International Clinical Trial: Safety and Efficacy of High-Dose ¹77Lu-PSMA versus ²²5Ac-PSMA for the Treatment of ¹77Lu-Refractory Prostate Cancer: A Phase II Clinical Study

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131867) titled 'Safety and Efficacy of High-Dose ¹77Lu-PSMA versus ²²5Ac-PSMA for the Treatment of ¹77Lu-Refractory Prostate Cancer: A Phase II Clinical Study' on Sept. 7.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The Affiliated Hospital of Southwest Medical University

Condition: metastatic castration resistant prostate cancer

Intervention: High-Dose 177Lu-PSMA group:High-dose 177Lu-PSMA therapy

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-09-15

Target Sample Size: High-Dose 177Lu-PSMA group:25;225Ac-PSMA group:25;

Countries of Recr...